- Home
- CTLT
CTLT
Catalent Inc.
as 07-26-2024 4:00pm EST
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SOMERSET |
| Market Cap: | 10.3B | IPO Year: | 2014 |
| Target Price: | $55.65 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.80 - $60.20 | Next Earning Date: | 08-27-2024 |
| Revenue: | $4,135,000,000 | Revenue Growth: | -8.01% |
| Revenue Growth (this year): | 3.5% | Revenue Growth (next year): | 6.26% |
Stock Insider Trading Activity of Catalent Inc. (CTLT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Masanovich Matti | CTLT | SVP, Chief Financial Officer | Jul 8 '24 | Sell | $56.74 | 2,993 | $169,822.82 | 33,871 | SEC Form 4 |
| Hopson Ricky | CTLT | Pres. BioProduct Delivery, CoS | Jun 4 '24 | Sell | $54.26 | 1,401 | $76,022.60 | 20,617 | SEC Form 4 |
| Gunther Scott | CTLT | SVP, Quality & Reg. Affairs | Mar 15 '24 | Sell | $56.20 | 387 | $21,749.40 | 29,506 | SEC Form 4 |
Latest Catalent Inc. News
CTLT Breaking Stock News: Dive into CTLT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
CTLT: What does Argus have to say about CTLT?
Simply Wall St.
3 days ago
Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?
Zacks
9 days ago
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Argus Research
10 days ago
CTLT: Raising target price to $61.00
Zacks
10 days ago
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Zacks
10 days ago
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
MT Newswires
11 days ago
Catalent Completes $25 Million Expansion of Schorndorf Site
Business Wire
11 days ago
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
Compare CTLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTLT Catalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.